548 related articles for article (PubMed ID: 28424535)
1. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus.
Polansky H; Itzkovitz E; Javaherian A
Drug Des Devel Ther; 2017; 11():575-583. PubMed ID: 28424535
[TBL] [Abstract][Full Text] [Related]
2. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir.
Polansky H; Javaherian A; Itzkovitz E
Drug Des Devel Ther; 2016; 10():2713-22. PubMed ID: 27621592
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes.
Polansky H; Javaherian A; Itzkovitz E
J Evid Based Integr Med; 2018; 23():2515690X18806269. PubMed ID: 30362389
[TBL] [Abstract][Full Text] [Related]
4. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.
Polansky H; Itzkovitz E; Javaherian A
Clin Transl Med; 2016 Dec; 5(1):40. PubMed ID: 27766602
[TBL] [Abstract][Full Text] [Related]
5. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.
Polansky H; Lori G
J Evid Based Integr Med; 2020; 25():2515690X20932523. PubMed ID: 32551855
[TBL] [Abstract][Full Text] [Related]
6. Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection.
Polansky H; Lori G
Int J Antimicrob Agents; 2020 Jun; 55(6):105971. PubMed ID: 32283177
[No Abstract] [Full Text] [Related]
7. The efficacy of vaginal suppository based on myrtle in patients with cervicovaginal human papillomavirus infection: A randomized, double-blind, placebo trial.
Nikakhtar Z; Hasanzadeh M; Hamedi SS; Najafi MN; Tavassoli AP; Feyzabadi Z; Meshkat Z; Saki A
Phytother Res; 2018 Oct; 32(10):2002-2008. PubMed ID: 29943384
[TBL] [Abstract][Full Text] [Related]
8. Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia.
Lin CT; Qiu JT; Wang CJ; Chang SD; Tang YH; Wu PJ; Jung SM; Huang CC; Chou HH; Jao MS; Lai CH
Taiwan J Obstet Gynecol; 2012 Dec; 51(4):533-8. PubMed ID: 23276555
[TBL] [Abstract][Full Text] [Related]
9. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
Insinga RP; Dasbach EJ; Elbasha EH; Liaw KL; Barr E
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):709-15. PubMed ID: 17416761
[TBL] [Abstract][Full Text] [Related]
10. Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally.
Guo X; Qiu L; Wang Y; Wang Y; Meng Y; Zhu Y; Lu L; Jiang S
J Med Virol; 2016 Jun; 88(6):1098-101. PubMed ID: 26629967
[TBL] [Abstract][Full Text] [Related]
11. Impact of human immunodeficiency virus on the natural history of human papillomavirus genital infection in South African men and women.
Mbulawa ZZ; Marais DJ; Johnson LF; Coetzee D; Williamson AL
J Infect Dis; 2012 Jul; 206(1):15-27. PubMed ID: 22517913
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia.
Terlou A; van Seters M; Kleinjan A; Heijmans-Antonissen C; Santegoets LA; Beckmann I; van Beurden M; Helmerhorst TJ; Blok LJ
Int J Cancer; 2010 Dec; 127(12):2831-40. PubMed ID: 21351262
[TBL] [Abstract][Full Text] [Related]
13. Anal human papillomavirus in HIV-uninfected men who have sex with men: incidence and clearance rates, duration of infection, and risk factors.
Donà MG; Vescio MF; Latini A; Giglio A; Moretto D; Frasca M; Benevolo M; Rollo F; Colafigli M; Cristaudo A; Giuliani M
Clin Microbiol Infect; 2016 Dec; 22(12):1004.e1-1004.e7. PubMed ID: 27585942
[TBL] [Abstract][Full Text] [Related]
14. HPV proteins as targets for therapeutic intervention.
Sterlinko Grm H; Banks L
Antivir Ther; 2004 Oct; 9(5):665-78. PubMed ID: 15535404
[TBL] [Abstract][Full Text] [Related]
15. Incidence, clearance and predictors of human papillomavirus infection in women.
Sellors JW; Karwalajtys TL; Kaczorowski J; Mahony JB; Lytwyn A; Chong S; Sparrow J; Lorincz A;
CMAJ; 2003 Feb; 168(4):421-5. PubMed ID: 12591782
[TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
17. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men.
Giuliano AR; Lu B; Nielson CM; Flores R; Papenfuss MR; Lee JH; Abrahamsen M; Harris RB
J Infect Dis; 2008 Sep; 198(6):827-35. PubMed ID: 18657037
[TBL] [Abstract][Full Text] [Related]
18. The clearance of oral high-risk human papillomavirus infection is impaired by long-term persistence of cervical human papillomavirus infection.
Louvanto K; Rautava J; Syrjänen K; Grénman S; Syrjänen S
Clin Microbiol Infect; 2014 Nov; 20(11):1167-72. PubMed ID: 24890849
[TBL] [Abstract][Full Text] [Related]
19. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.
Snoeck R; Bossens M; Parent D; Delaere B; Degreef H; Van Ranst M; Noël JC; Wulfsohn MS; Rooney JF; Jaffe HS; De Clercq E
Clin Infect Dis; 2001 Sep; 33(5):597-602. PubMed ID: 11477525
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up.
Branca M; Garbuglia AR; Benedetto A; Cappiello T; Leoncini L; Migliore G; Agarossi A; Syrjänen K;
Int J STD AIDS; 2003 Jun; 14(6):417-25. PubMed ID: 12816671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
